Snow R, Babish J D, McBean A M
University of Minnesota School of Public Health, Division of Health Management and Policy, USA.
Public Health Rep. 1995 Nov-Dec;110(6):720-5.
To learn whether the risk of revaccination in adults should limit its use, the authors investigated whether adverse events requiring hospitalization occurred in a group of Medicare enrollees revaccinated with pneumococcal polysaccharide vaccine. A prospective cohort analysis and case study of revaccinated people involved five percent of all elderly Medicare enrollees from 1985 through 1988, consisting of 66,256 people receiving one dose of vaccine and 1,099 receiving two doses. Comparison was made of the hospitalization rate within 30 days after revaccination and rates of singly vaccinated persons using discharge diagnosis for all those hospitalized during the 30 days after revaccination. No significant difference was found between the hospitalization rate of the revaccinated cohort and comparison group. No adverse reactions attributable to pneumococcal polysaccharide vaccine causing hospitalization were identified among 39 revaccinated persons who were hospitalized within 30 days of revaccination. Revaccination of elderly Medicare beneficiaries does not cause events serious enough to require hospitalization. Vaccination of persons according to the Public Health Service Immunization Practice Advisory Committee guidelines is recommended when the prior immunization status is unknown.
为了了解成人再次接种疫苗的风险是否会限制其使用，作者调查了一组接受肺炎球菌多糖疫苗再次接种的医疗保险参保人中是否发生了需要住院治疗的不良事件。对再次接种者进行的前瞻性队列分析和案例研究涉及了1985年至1988年所有老年医疗保险参保人的5%，包括66256名接种一剂疫苗的人和1099名接种两剂疫苗的人。通过再次接种后30天内的住院率与使用再次接种后30天内所有住院者出院诊断的单次接种者的住院率进行比较。再次接种队列与对照组的住院率之间未发现显著差异。在再次接种后30天内住院的39名再次接种者中，未发现可归因于肺炎球菌多糖疫苗导致住院的不良反应。老年医疗保险受益人的再次接种不会引发严重到需要住院治疗的事件。当先前的免疫状况未知时，建议按照公共卫生服务免疫实践咨询委员会的指南对人员进行疫苗接种。
